Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease
|ClinicalTrials.gov Identifier: NCT00382564|
Recruitment Status : Completed
First Posted : September 29, 2006
Last Update Posted : October 6, 2017
This study will determine the usefulness of magnetic resonance imaging (MRI) for examining the heart or blood vessels. MRI uses a magnetic field and radio waves to produce images of body tissues and organs. The subject lies on a table that can slide in and out of the scanner (a metal cylinder), wearing earplugs to muffle loud noises that occur during the scanning process. MRI of the heart and blood vessels, called magnetic resonance angiography (MRA), is a developing diagnostic method that permits evaluation of arteries and veins without the use of x-rays or invasive catheterization required by conventional angiography.
People 18 years of age and older with known or suspected atherosclerotic disease may be eligible for this study.
Participants have blood tests and MRA scanning. The MRA takes about 1.5 to 2 hours. During part of the scan, a contrast agent may be injected into a vein to brighten the images of the heart and blood vessels. Subjects are monitored with an electrocardiogram and are asked to hold their breath for about 5 to 20 seconds intermittently during the procedure.
A CT scan may be done to confirm the MRA findings. CT uses x-rays to produce pictures of the heart and blood vessels. The subject lies on a bed during the scan and is given a contrast agent through a catheter inserted into a vein. Subjects are asked to hold their breath intermittently for about 5 to 20 seconds. A medicine called a beta blocker may be administered to slow the heart rate.
|Condition or disease|
|Atherosclerosis Hyperlipidemia Hypertension Diabetes Mellitus|
|Study Type :||Observational|
|Actual Enrollment :||216 participants|
|Official Title:||Magnetic Resonance Angiography (MRA) in the Diagnosis of Atherosclerotic Disease Using High Field (3T) MRI Scanners: A Pilot Technical Development Study|
|Study Start Date :||September 25, 2006|
|Estimated Study Completion Date :||May 1, 2012|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00382564
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Ahmed M Gharib, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|